Gregory D. Flexter
Fondateur chez Blue Ash Therapeutics LLC
Profil
Gregory D.
Flexter is the founder and CEO & Director of Blue Ash Therapeutics LLC since 2008.
He was the President & CEO of Xanodyne Pharmaceuticals, Inc. and Director-Global Commercial Development of Marion Merrell Dow, Inc. He was also the EVP & General Manager-North America of Shire Plc from 2001 to 2006.
Additionally, he held the position of Vice President & Head-Neuroscience at Novartis Pharmaceuticals UK Ltd.
and Vice President-Marketing & Medical Research at Hoechst Marion Roussel Ltd.
(United Kingdom).
He started his career as a Principal at Marion Laboratories.
Mr. Flexter completed his undergraduate degree from the University of Missouri.
Postes actifs de Gregory D. Flexter
| Sociétés | Poste | Début |
|---|---|---|
Blue Ash Therapeutics LLC
 Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | Fondateur | 30/04/2010 |
Anciens postes connus de Gregory D. Flexter
| Sociétés | Poste | Fin |
|---|---|---|
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/07/2006 |
| Marion Laboratories | Corporate Officer/Principal | - |
Xanodyne Pharmaceuticals, Inc.
 Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | President | - |
Hoechst Marion Roussel Ltd. (United Kingdom)
 Hoechst Marion Roussel Ltd. (United Kingdom) Pharmaceuticals: OtherHealth Technology Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the company is based in Guildford, UK. | Directeur Technique/Scientifique/R&D | - |
| Marion Merrell Dow, Inc. | Corporate Officer/Principal | - |
Formation de Gregory D. Flexter
| University of Missouri | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Novartis Pharmaceuticals UK Ltd.
 Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Health Technology |
| Marion Merrell Dow, Inc. | Health Technology |
Hoechst Marion Roussel Ltd. (United Kingdom)
Hoechst Marion Roussel Ltd. (United Kingdom) Pharmaceuticals: OtherHealth Technology Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the company is based in Guildford, UK. | Health Technology |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |
| Marion Laboratories | Distribution Services |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | Health Technology |